Sanofi Reports Superior Protection For Older Adults With High-Dose Influenza Vaccine

(RTTNews) - Sanofi SA (SNY) announced that new data from the FLUNITY-HD study showed its high-dose influenza vaccine significantly reduces the risk of hospitalization in adults aged 65 and older compared to standard-dose flu vaccines.

Compared to standard-dose influenza vaccines, Efluelda (also known as Fluzone High-Dose) demonstrated an additional 31.9% reduction in laboratory-confirmed influenza-related hospitalizations in adults 65 years and older.

The findings come from FLUNITY-HD, the largest influenza vaccine effectiveness study conducted in individually randomized older adults. The study included nearly half a million participants across multiple flu seasons and two distinct geographic regions.

Beyond influenza-related hospitalizations, Efluelda/Fluzone High-Dose also provided superior protection against hospitalizations due to pneumonia or influenza, cardio-respiratory events, and all-cause hospitalizations in older adults when compared to standard-dose influenza vaccines.

With the addition of these new data, our high-dose influenza vaccine is now supported by 15 years of clinical evidence, encompassing over 45 million older adults.

Efluelda/Fluzone High-Dose is the first vaccine to demonstrate superior protection against both influenza infection and related hospitalizations in individually randomized studies involving adults aged 65 and older, Sanofi said.

For More Such Health News, visit rttnews.com.